

Eiger BioPharmaceuticals to Participate in Two Investor Conferences in November 2016

PALO ALTO, Calif., November 21, 2016, Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical stage biopharmaceuticals company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will participate in two upcoming investor conferences in November 2016, providing a corporate overview and business update in group and individual meetings.

- 2016 Oppenheimer Life Sciences Summit, Sofitel Hotel, New York City, November 29, 2016, individual meeting format
- Piper Jaffray 28th Annual Healthcare Conference, Lotte New York Palace Hotel, New York City, November 30, 2016, 12:30 pm ET, “Fireside Chat” format

A live webcast of the Piper Jaffray session will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

About Eiger

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.



SOURCE Eiger Bio, Inc.

Investors: Andrew McDonald LifeSci Advisors, LLC, 646-597-6987,
andrew@lifesciadvisors.com